In ongoing treatments, the last data point refers to the time of the last documented administration of a degarelix dose. Change in PSA, S-ALP, and prostate volume are summarized using descriptive ...

A study showed that patients with prostate cancer should consider the long-term side effects of treatments before deciding on ...

NICE has published final guidance recommending funding for Ferring’s Firmagon (degarelix) treatment for hormone-dependent prostate cancer. The decision followed a successful appeal by Ferring ...

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

A total of 1,010 patients received degarelix and were included. Baseline demographic and disease characteristics of the registry population are summarized in Table 2. Around two-thirds of patients ...